Biotech stocks could be a big opportunity for exponentialBiotech stocks could be a big opportunity for exponential gains.
Biotech stocks are always in the spotlight as the sector itself has been the source of significant disruptions for the global healthcare system. Long sought after by both high-risk investors and low-risk investors, biotechnology stocks offer something that other stocks do not: highly speculative opportunities. Because many of these companies are involved in early-phase trials of things like novel drugs, a positive result at any phase can end up producing a favorable reaction in the stock market. And for biotech stock investors, this could be a big opportunity for exponential gains.
Regencell Bioscience is an early-clinical bioscience company that focuses on the research and development of Traditional Chinese Medicine (TCM) to holistically treat neurocognitive disorders and also infectious diseases that affect the immune system, such as COVID-19.
The company has been researching and conducting studies to address the fundamental causes of ADHD and ASD disorders. The goal is to improve the lives of ADHD and ASD patients, their families, and caregivers and to become a market leader for the treatment of these disorders. rGC aims to achieve improvements in both symptoms and overall health of patients as compared to currently available medications on the market. They are passionate about transforming the lives of patients, their families and caregivers and helping them feel their best physically, mentally, and emotionally.
Nasdaq Listing
On July 16, 2021, the ordinary shares began trading on the Nasdaq Capital Market. The company raised net proceeds of approximately $19.3 million from the initial public offering of 2,300,000 ordinary shares at a public offering price of $9.50 per share. They plan to use these proceeds to fund the second research study (currently ongoing), TCM formula and products, staff salaries, product and intellectual property registrations, facilities rental, renovations, and equipment, for working capital and other general corporate purposes.
The company launches three liquid based standardized TCM formula candidates for mild, moderate and severe ADHD and ASD patients. The company made a stellar performance after its IPO and gained 223% since then.
All directors and employees who were previously granted stock options have agreed to a further lock-up undertaking for an additional six months, until July 20, 2023, the second anniversary of the company's initial public offering. Their shares will remain locked up until such date.